Influence of estrogen therapy on calcium, phosphorus, and other regulatory hormones in postmenopausal women: The MESA study

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages 4890-4898

  Bansal, Nisha ^a   Katz, Ronit ^b   De Boer, Ian H ^a   Kestenbaum, Bryan ^a   Siscovick, David S ^a   Hoofnagle, Andrew N ^a   Tracy, Russell ^c   Laughlin, Gail A ^d   Criqui, Michael H ^d   Budoff, Mathew J ^f   Li, Dong ^f   Ix, Joachim H ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Outcomes Res Mid Amer Heart I   (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d University of Vermont ^*  (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; CALCIUM; ESTROGEN; FIBROBLAST GROWTH FACTOR 23; HORMONE; PHOSPHORUS;

ABDOMINAL RADIOGRAPHY; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CALCIUM URINE LEVEL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ESTROGEN THERAPY; ETHNIC DIFFERENCE; FEMALE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MIDDLE AGED; MINERAL METABOLISM; PHOSPHATE BLOOD LEVEL; PHOSPHATE URINE LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VITAMIN BLOOD LEVEL;

24,25-DIHYDROXYVITAMIN D 3; 25-HYDROXYVITAMIN D 2; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; CALCIFEDIOL; CALCIUM; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ERGOCALCIFEROLS; ESTROGEN REPLACEMENT THERAPY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHOSPHORUS; VITAMIN D;

EID: 84889805926     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2286     Document Type: Article

References (42)

1. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738.
2. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA. 2002;287:2668-2676.
3. Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA. 2001;286:815-820.
4. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab. 2001;86:3618-3628.
5. Stock JL, Coderre JA, Mallette LE. Effects of a short course of estrogen on mineral metabolism in postmenopausal women. J Clin Endocrinol Metab. 1985;61:595-600.
6. Kulak CA, Baz-Hecht M, Nieves J, Shen V, Lindsay R, Cosman F. Responses of urinary N- telopeptide and renal calcium handling to PTH infusion after treatment with estrogen, raloxifene, and tamoxifen. Calcif Tissue Int. 2012;90:263-271.
7. Devine A, Prince RL, Kerr DA, et al. Correlates of intestinal calcium absorption inwomen10 years past the menopause. Calcif Tissue Int. 1993;52:358-360.
8. Wishart JM, Scopacasa F, Horowitz M, et al. Effect of perimenopause on calcium absorption: a longitudinal study. Climacteric. 2000;3:102-108.
9. Prince RL, Dick I, Devine A, et al. The effects of menopause and age on calcitropic hormones: a cross-sectional study of 655 healthy women aged 35 to 90. J Bone Miner Res. 1995;10:835-842.
10. Robinson-Cohen C, Hoofnagle AN, Ix JH, et al. Racial differences in the association of serum 25-hydroxyvitamin D concentration with coronary heart disease events. JAMA. 2013;310:179-188.
11. Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the heart and soul study. Am J Kidney Dis. 2011;58:737-745.
12. Faroqui S, Levi M, Soleimani M, Amlal H. Estrogen downregulates the proximal tubule type 2a sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia. Kidney Int. 2008; 73:1141-1150.
13. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1α,25-dihydroxyvitamin D3 production. J Biol Chem. 2003;278:2206-2211.
14. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003- 4008.
15. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design.AmJ Epidemiol. 2002;156:871-881.
16. Strathmann FG, Laha TJ, Hoofnagle AN. Quantification of 1 α,25-dihydroxy vitamin D by immunoextraction and liquid chromatography- tandem mass spectrometry. Clin Chem. 2011;57:1279-1285.
17. Li D, Mao SS, Khazai B, et al. Noncontrast cardiac computed tomography image-based vertebral bone mineral density: the Multi- Ethnic Study of Atherosclerosis (MESA). Acad Radiol. 2013;20: 621-627.
18. Breen JF, Sheedy PF 2nd, Schwartz RS, et al. Coronary artery calcification detected with ultrafast CT as an indication of coronary artery disease. Radiology. 1992;185:435-439.
19. Carr JJ, Nelson JC, Wong ND, et al. Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2005;234:35-43.
20. Cann CE. Quantitative CT for determination of bone mineral density: a review. Radiology. 1988;166:509-522.
21. Hyder JA, Allison MA, Barrett-Connor E, et al. Bone mineral density and atherosclerosis: the Multi-Ethnic Study of Atherosclerosis, Abdominal Aortic Calcium Study. Atherosclerosis. 2010;209:283-289.
22. Duprez DA, Jacobs DR, Lutsey PL, et al. Association of small artery elasticity with incident cardiovascular disease in older adults: the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol. 2011;174: 528-536.
23. Aaron CP, Tandri H, Barr RG, et al. Physical activity and right ventricular structure and function. The MESA-Right Ventricle Study. Am J Respir Crit Care Med. 2011;183:396-404.
24. Stevens L, Coresh J, Schmid C, et al. Estimating GFR using serum cystatinCalone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008; 51:395-406.
25. Nemere I. Apparent nonnuclear regulation of intestinal phosphate transport: effects of 1,25- dihydroxyvitamin D3,24,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3. Endocrinology. 1996;137: 2254-2261.
26. Nemere I. 24,25-Dihydroxyvitamin D3 suppresses the rapid actions of 1, 25-dihydroxyvitaminD3and parathyroid hormone on calcium transport in chick intestine. J Bone Miner Res. 1999;14:1543-1549.
27. Bosworth CR, Levin G, Robinson-Cohen C, et al. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int. 2012;82:693-700.
28. Adami S, Gatti D, Bertoldo F, et al. The effects of menopause and estrogen replacement therapy on the renal handling of calcium. Osteoporos Int. 1992;2:180-185.
29. Stock JL, Coderre JA, Posillico JT. Effects of estrogen on mineral metabolism in postmenopausal women as evaluated by multiple assays measuring parathyrin bioactivity. Clin Chem. 1989;35: 18-22.
30. McKane WR, Khosla S, Burritt MF, et al. Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause - a clinical research center study. J Clin Endocrinol Metab. 1995;80:3458-3464.
31. Heshmati HM, Khosla S, Burritt MF, O'Fallon WM, Riggs BL. A defect in renal calcium conservation may contribute to the pathogenesis of postmenopausal osteoporosis. J Clin Endocrinol Metab. 1998;83:1916-1920.
32. Dick IM, Devine A, Beilby J, Prince RL. Effects of endogenous estrogen on renal calcium and phosphate handling in elderly women. Am J Physiol Endocrinol Metab. 2005;288:E430-435.
33. Kaplan B, Neri A, Kitai E, Pardo Y, Blum M, Friedman J. Low dose estrogen replacement therapy in early postmenopausal women effect on urinary magnesium and calcium: creatinine ratios. Clin Exp Obstet Gynecol. 1994;21:170-172
34. Meng J, Ohlsson C, Laughlin GA, et al. Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study. Kidney Int. 2010;78:415-422.
35. Khanal RC, Smith NM,Nemere I. Phosphate uptake in chick kidney cells: effects of 1,25(OH)2D3 and 24,25(OH)2D3. Steroids. 2007; 72:158-164.
36. Ono T, Tanaka H, Yamate T, Nagai Y, Nakamura T, Seino Y. 24R,25-Dihydroxyvitamin D3 promotes bone formation without causing excessive resorption in hypophosphatemic mice. Endocrinology. 1996;137:2633-2637.
37. Seo EG, Einhorn TA, Norman AW. 24R,25-Dihydroxyvitamin D3: an essential vitamin D3 metabolite for both normal bone integrity and healing of tibial fracture in chicks. Endocrinology. 1997;138: 3864-3872
38. Wang H, Yoshiko Y, Yamamoto R, et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008;23:939-948.
39. Sitara D, Kim S, Razzaque MS, et al. Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet. 2008;4:e1000154.
40. Marsell R, MirzaMA,Mallmin H, et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int. 2009;20:1167-1173.
41. Holecki M, Chudek J, Wiecek A, Titz-Bober M, Dulawa J. The serum level of fibroblast growth factor-23 and calcium-phosphate homeostasis in obese perimenopausal women. Int J Endocrinol. 2011;2011:707126.
42. Lindsay R. The role of estrogen in the prevention of osteoporosis. Endocrinol Metab Clin North Am. 1998;27:399-409.